Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Auditor change
Evoke Pharma Inc (EVOK) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Investor Contact: Daniel Kontoh-Boateng DKB Partners Tel: 862-213-1398"
03/21/2023 8-K Quarterly results
Docs: "Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021 Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif., March 21, 2023 -- Evoke Pharma, Inc. , a specialty pharmaceutical company focused primarily on treatments for gastrointestinal diseases with an emphasis on GIMOTI® nasal spray, today announced its financial results for the fourth quarter and full year ended December 31, 2022, and recent corporate developments. “Evoke’s fiscal year 2022 was a period of tremendous growth and progress on several key fronts. Year-over-year revenues, new prescribers, prescription fills, and patient enrollments showed significant improvement in 2022 compared ..."
11/09/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/08/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Evoke Pharma Reports Third Quarter 2021 Financial Results"
08/12/2021 8-K Quarterly results
Docs: "Evoke Pharma Reports Second Quarter 2021 Financial Results Approximately 162% growth in product sales, 152% growth in prescriptions and 57% increase in new prescribers for Gimoti ® Extends cash runway into third quarter of 2022"
03/11/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "Evoke Pharma Reports Third Quarter 2020 Financial Results Gimoti™ commercial launch underway"
08/06/2020 8-K Quarterly results
05/12/2020 8-K Quarterly results
Docs: "Evoke Pharma Reports First Quarter 2020 Financial Results and Changes its 2020 Annual Meeting of Stockholders to a Virtual Format Gimoti™ Prescription Drug User Fee Act date is June 19, 2020"
03/12/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Evoke Pharma Reports Third Quarter 2019 Financial Results Gimoti NDA resubmission on track for fourth quarter 2019"
08/08/2019 8-K Quarterly results
05/08/2019 8-K Quarterly results
Docs: "Evoke Pharma Reports First Quarter 2019 Financial Results Projected cash runway extended to first quarter 2020"
03/06/2019 8-K Quarterly results
Docs: "Evoke Pharma Fourth Quarter and Full Year 2018 Financial Results and FDA Communication"
08/09/2018 8-K Quarterly results
Docs: "Evoke Pharma Reports Second Quarter 2018 Results and Recent Highlights Gimoti ™ NDA submitted to FDA on June 1st ; awaiting 74-Day FDA filing communication letter Gender-specific patents granted for Gimoti in the European Union and Mexico"
05/14/2018 8-K Quarterly results
03/07/2018 8-K Quarterly results
Docs: "Evoke Pharma Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights • Successfully completed pivotal pharmacokinetic trial and finalized the proposed to-be-marketed Gimoti™ dose • Announced discovery of sex-based pharmacokinetic differences for Gimoti™ • Met with FDA regarding NDA women-only filing strategy and post-marketing plans • 505 NDA submission planned for second quarter of 2018"
11/14/2017 8-K Quarterly results
Docs: "Evoke Pharma Reports Third Quarter 2017 Results and Highlights"
08/14/2017 8-K Quarterly results
05/15/2017 8-K Form 8-K - Current report
03/15/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
05/11/2016 8-K Form 8-K - Current report
03/10/2016 8-K Form 8-K - Current report
11/12/2015 8-K Quarterly results
Docs: "Evoke Pharma Reports Third Quarter 2015 Results Enhanced financial strength and further progressed trial enrollment"
08/13/2015 8-K Quarterly results
Docs: "Evoke Pharma Reports Second Quarter 2015 Results Enrolled 130 total subjects in Phase 3 clinical trial through end of July Recent FDA draft guidance of advice on Gastroparesis mirrors Evoke’s Phase 3 clinical trial protocol design"
05/14/2015 8-K Quarterly results
Docs: "Evoke Pharma Reports First Quarter 2015 Results Company begins preparation for commercialization of EVK-001"
03/04/2015 8-K Quarterly results
Docs: "Evoke Pharma Reports Fourth Quarter and Year End 2014 Results"
05/13/2014 8-K Quarterly results
Docs: "Evoke Pharma Reports First Quarter 2014 Results"
03/25/2014 8-K Quarterly results
Docs: "Evoke Pharma Reports Fourth Quarter and Year End 2013 Results"
11/13/2013 8-K Quarterly results
Docs: "Evoke Pharma Reports Third Quarter 2013 Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy